TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03375151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG based feedback
Description: Participants will participate in cognitive training sessions. The therapist will use feedback from the EEG analyzed data to direct the cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard practice based feedback
Description: Participants will participate in cognitive training sessions. The therapist will give feedback to the participants during the exercise based on their performance only according to the his therapist standard practice.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard practice based feedback
Description: Participants will participate in cognitive training sessions. The therapist will give feedback to the participants during the exercise based on their performance only according to the his therapist standard practice.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No feedback
Description: Participants will participate in cognitive training sessions. The therapist will not guide them during the sessions.
Study: NCT02650544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
Study: NCT01833923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib
Description: oral medicine.
Study: NCT03467386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo alloHCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administer according to City of Hope standard operating procedures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given CIV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Undergo TMLI
Study: NCT01781585

Intervention type: PROCEDURE
Intervention: hemodialysis
Description: Patients were randomized to receive CVVH or SLED and the next day on the other.

Intervention type: PROCEDURE
Intervention: hemodialysis
Description: Patients were randomized to receive CVVH or SLED and the next day on the other.
Study: NCT04456725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive management
Description: The intervention group will be assigned to a partnership of one nurse practitioner and one medical assistant who will manage them intensively, with the support of the study team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual care
Study: NCT04186468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICU follow-up clinic
Description: The intervention aims at improving health-related quality of life and will contain three components: information, consultation and networking. More information will be available for the participants from the intensive care stay onwards, e.g. an information brochure, and during the entire follow-up period, e.g. by contacting the outpatient clinic via telephone. Participants will be invited to visit the ICU follow-up clinic at least once during the first six months after discharge from ICU. During the visits, participants will be screened for symptoms of PICS and, if required, referred to specialists for further treatment. The aim of the networking part is to improve the exchange between the health sectors and disciplines, e.g. through a special referral letter from the ICU follow-up clinic, and thus to provide a network of outpatient care providers for the former ICU patients.
Study: NCT00709358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of microbial DNA in blood by SeptiFast®
Description: The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.~Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: detection of microbial DNA in blood by blood culture
Description: A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
Study: NCT01839526

Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol
Description: Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
Study: NCT03632759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Participants will receive subcutaneous (SC) liraglutide for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive subcutaneous (SC) golimumab for 8 weeks
Study: NCT05855291

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: The participants receive 18F-FDG PET/MRI before and after neoadjuvant chemoradiotherapy.
Study: NCT03840122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACB + IPACK block with injection of local anesthetic
Description: ACB + IPACK block with injection of local anesthetic which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACB + IPACK block without injection
Description: ACB + IPACK block without an injection of local anesthetic
Study: NCT05468398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soothe VR
Description: The Soothe VR system is manufactured by Applied VR. It is a HIPAA-compliant platform and has been validated by randomized control trials. It has not yet been reviewed by the FDA.
Study: NCT01805726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: (D) Local anesthesia 1% 25 ml in total (bronchoscopy) + dexmedetomidine 0.5 mcg / kg (slow perfusion for 10 minutes) + 2 ml saline (slow injection for 5 seconds)
Study: NCT03875937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic 1 gram
Description: To be administered intramuscularly (2 injections)
Study: NCT03045237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercises classes
Description: 3 physical exercises classes, one of them in the pool.
Study: NCT00701974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase (IRUXOL)
Description: patients will be treated with collagenase one time per day.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase (Kollagenase)
Description: patients will be treated with collagenase one time per day.
Study: NCT05495113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YMS-201B (Device: Mind STIM)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation using YMS-201B
Description: Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study: NCT02009748

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation
Description: oral administration of colecalciferol 2.800 IU once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo (vehicle) once daily
Study: NCT04322149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1501
Description: AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Study: NCT04470375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Pain Neuroscience Education
Description: Use of virtual reality media to provide pain neuroscience education
Study: NCT02359695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
Study: NCT01021813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Oral tablet (30 mg and 10 mg), administered daily before bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose-matched Placebo to Suvorexant
Description: Oral tablet, administered daily before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to Suvorexant
Description: Oral tablet, administered daily before bedtime
Study: NCT03522701

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTI
Description: Refer to the arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTI
Description: Refer to the arm description
Study: NCT03716518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonifying Spleen and Kidney Sequential Regimen
Description: TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of 'Tonifying Spleen and Kidney Sequential Regimen
Description: Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.
Study: NCT02992158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral activation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: treatment-as-usual
Description: psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
Study: NCT03900754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal administration of oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02219633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 39652 cream
Description: Applied for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 39652 cream
Description: Applied for 21 days
Study: NCT03160105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to DTG + FTC
Description: Switch from standard cART to DTG + FTC dual maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to DTG + FTC
Description: Switch from standard cART to DTG + FTC dual maintenance therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-centered monitoring
Description: Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-centered monitoring
Description: Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
Study: NCT04394455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy
Description: 9 structured psychotherapy sessions, weekly, 60-90 minutes duration. Provided by one therapist and one co-therapist. Provided through telepsychiatry.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crisis intervention therapy
Description: 3 structured sessions of crisis intervention. One session each week for three weeks. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
Study: NCT04352595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay808
Description: Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay808
Description: Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay808
Description: Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay808
Description: Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
Study: NCT02077387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHild Inhibitory Control (CHIC) Play
Description: CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: Children will receive an equal amount of time with the RA, but focus on other healthy behaviors and not use inhibitory control skills training techniques
Study: NCT01648452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NT-501 CNTF-releasing implant
Description: 20 ng/day released into the eye
Study: NCT04109872

Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
Study: NCT03963934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program on a nurse-led telephone 6-month-follow-up for uncontrolled hypertensive women: a patient-tailored intervention
Description: Implementation of personalized support: The accompaniment includes 7 telephone interviews for 6 months (understanding the antihypertensive treatment, identifying the brakes and the levers when taking medication, organizing the treatment taking, making the home blood pressure)
Study: NCT02698813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells and hyaluronic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Study: NCT01845428

Intervention type: DRUG
Group type: OTHER
Intervention: Pravastatin
Description: After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
Study: NCT00807937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: 4 tablets and 1 capsule taken twice a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: 4 tablets and 1 capsule taken twice a day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: 4 tablets and 1 capsule taken twice a day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets and 1 capsule taken twice a day for 28 days
Study: NCT04338893

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Persona Total Knee
Description: The choice of intervention is defined by surgeons standard use of device 'Persona' in their standard of care practice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Persona Total Knee
Description: The choice of intervention is defined by surgeons standard use of device 'Persona' in their standard of care practice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: NexGen Total Knee
Description: The choice of intervention is defined by surgeons standard use of device 'Nexgen' in their standard of care practice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: NexGen Total Knee
Description: The choice of intervention is defined by surgeons standard use of device 'Nexgen' in their standard of care practice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Vanguard Total Knee
Description: The choice of intervention is defined by surgeons standard use of device 'Vanguard' in their standard of care practice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Vanguard Total Knee
Description: The choice of intervention is defined by surgeons standard use of device 'Vanguard' in their standard of care practice
Study: NCT02449863

Intervention type: OTHER
Intervention: Lung ultrasound
Description: Lung ultrasound performed to newborns with respiratory distress

Intervention type: OTHER
Intervention: Lung ultrasound
Description: Lung ultrasound performed to newborns with respiratory distress
Study: NCT01865149

Intervention type: PROCEDURE
Intervention: retrobulbar ultrasound
Description: both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
Study: NCT01542593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR
Description: During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery).
Study: NCT04042129

Intervention type: OTHER
Intervention: gynecologic operations with urological complications
Study: NCT02502708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered on days 1-5 of every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered on days 1-5 of every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered on days 1-5 of every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered on days 1-5 of every 28 day cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal Radiation
Description: Conformal radiation will be administered on days 3-7 of induction cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal Radiation
Description: Conformal radiation will be administered on days 3-7 of induction cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered orally daily.
Study: NCT02708108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Beginning at time of diagnosis, the dietary component of the intervention uses a personalized menu to implement high protein, moderate fat, and low glycemic index/high fiber diet to achieve a minimum net -10% daily caloric deficit during the induction phase of chemotherapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity and Exercise Intervention
Description: Beginning at the time of diagnosis, the exercise and activity component uses an activity menu to implement a target level of 200 minutes per week of moderate exercise activity (as estimated by metabolic equivalents) during the induction phase of chemotherapy.
Study: NCT03588715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha 2b (peg-IFN-α2b)
Description: Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117 + 10-1074
Description: Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117 + 10-1074
Description: Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.
Study: NCT03100513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: (lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol
Description: PEG as single dose of (3sachets if patient \<75Kg over 3 hours or 4 sachets if patient \>75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).